Posts, updates and videos about cannabis – updated automatically.
There are a lot of reasons to be delighted that Trump has fired his do nothing Attorney General. From the Canadian cannabis sector’s perspective, Sessions was a major road block to federal legalization efforts. Given the size of the potential US market as well as the difficulties created by the federal law in terms of investment, reasearch and even cross border travel, federal legalization would be a huge plus for the Canadian cannabis industry.
FSD Pharma (C.HUGE) Director, Anthony Durkacz discussed US legalization on The Midas Letter:
MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to announce its wholly owned subsidiary ZincNyx Energy Solutions Inc (“ZincNyx”) has signed a Strategic Partnership Agreement with Braingrid Corporation (“Braingrid”) to co-develop and market a packaged energy management product offering for the cannabis cultivation market. The partnership will leverage Braingrid’s software and technology, which uses proprietary sensing and control hardware and ZincNyc’s modular energy storage systems, which provide scalable regenerative zinc-air flow battery for mass storage of energy, to provide cannabis cultivators with renewable solutions for cultivation. ZincNyx and Braingrid have agreed to sign a Definitive Agreement within the next 60 days.
As noted by Braingrid, cannabis cultivation sites are growing exponentially in cultivation square footage. The electrical grid is incapable of supplying the demand or storing excess renewable production, especially in rural areas. Ideal cultivation zones which have inexpensive land and low community impact do not have access to the electrical grid to support the operation. Energy efficiency is too complicated and costly but at the same time, low cost energy solutions are required. Cannabis cultivators intending to survive the upcoming oversupply and the resultant “race to the bottom” will need to become extremely rigorous in reducing the cost per gram. Therefore, cultivators who have a fiscally driven understanding of their energy “footprint” and are independently autonomous from utility market prices through local storage and cogeneration will ensure their viability now and into the future.
Cannabis cultivation and energy facts:
- Cultivation is very energy and resource intensive:
- Most growers/operators are unfamiliar and disconnected with energy pricing and unfocused on energy efficiency due to high market cannabis prices.
- New laws are emerging in certain geographies which mandate farmers/cultivators employ real-time monitoring of water/electricity use.
- There are many government and utility incentives available to encourage a reduction in environmental impact.
- Electricity prices range from ~7￠/kWh(CAD$) to more than 15￠/kWh(CAD$) with more than ⅔ of cannabis cultivators paying ~14￠/kWh(CAD$) base. Peak demand charges greatly increases these costs.
- Electricity prices have outpaced inflation however renewable energy sources are mostly par with conventional energy sources (i.e. natural gas)
- Cultivators will be forced to utilize on-site cogeneration and peak shaving technologies such as solar, diesel, gas turbine (syngas/natural gas) to offset energy costs and make up for the utility grid stability.
- Energy overproduction often occurs for solar systems requiring energy storage for maximum benefit
Braingrid Executive Team
The Braingrid team is made up of a diverse group of executives and engineers including founder and CEO Michael Kadonoff, who previously worked as a professional hardware designer at General Electric Grid IQ on the premier design team for energy grid automation and control products. President & COO Matthew Skynner has over 25 years of high-tech experience, including leading a global, $1B technology business as Corporate Vice President and General Manager at AMD.
Braingrid Corporation is a global technology company that provides an affordable, versatile and quick-to-install cannabis cultivation intelligence system. Braingrid captures real-time data needed to increase revenues, reduce costs, risks and energy while connecting cultivators to their grow on a microclimate level.
About ZincNyx Energy Solutions
ZincNyx has developed a patented regenerative zinc-air flow battery that efficiently stores energy in the form of zinc particles and contains none of the traditional high cost battery commodities such as lithium, vanadium, or cobalt. The technology allows for low cost mass storage of energy and can be deployed into a wide range of applications.
Unlike conventional batteries, which have a fixed energy/power ratio, ZincNyx’s technology uses a fuel tank system that offers flexible energy/power ratios and scalability. The storage capacity is directly tied to the size of the fuel tank and the quantity of recharged zinc fuel, making scalability a major advantage of the flow battery system. In addition, a further major advantage of the zinc-air flow battery is the ability to charge and discharge simultaneously and at different maximum charge or discharge rates since each of the charge and discharge circuits is separate and independent. Other types of standard and flow batteries are limited to a maximum charge and discharge by the total number of cells as there is no separation of the charge, discharge and storage components.
The ZincNyx mission is to provide cost effective, long duration and reliable energy storage systems for markets involving renewables firming, peak shaving, diesel generator replacement, telecom facility back-up, electrification of ferries and tug boats and electric vehicle charging support. With a portfolio of 20 granted patents and an experienced management team, ZincNyx has begun mass production (see press release August 9, 2018). To learn more about ZincNyx technology visit www.zincnyx.com.
About MGX Minerals
MGX Minerals is a diversified Canadian resource and technology company with interests in global advanced material, energy, and water assets. Learn more at www.mgxminerals.com.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information or forward-looking statements (collectively “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is typically identified by words such as: “believe”, “expect”, “anticipate”, “intend”, “estimate”, “potentially” and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various factors. The reader is referred to the Company’s public filings for a more complete discussion of such risk factors and their potential effects which may be accessed through the Company’s profile on SEDAR at www.sedar.com.
Contact Information Jared Lazerson President and CEO Telephone: 1.604.681.7735 Web: www.mgxminerals.com
In the wake of FSD Pharma (C.HUGE) stunning all share takeover of NASDAQ listed Therapix Bioscience there is some analysis posted at Seeking Alpha.
You can read it at A HUGE step forward
Anthony Durkacz is just fun to watch.
Here he is on The Midas Letter.
A good, short, video overview of Cantab Therapeutics (C.PILL) on Investment Pitch.
Canntab has developed an extended release cannabis delivery system, a hard pill, which allows the dosage of cannabis products to be controlled precisely. It is a patentable technology and critical for the effective medical use of cannabis and cannabinoids in therapeutic settings.
The company has achieved a full-on licencing arrangement with a company in Colombia which will mean that Canntab’s products will be distributed in Colombia and a number of other Spanish speaking markets. As part of this arrangement, Canntab will receive an initial payment of 2 million US dollars. Hard cash for real intellectual property.
Excellent, short, video about FSD Pharma’s cannabis grow facility in ex-Kraft Foods plant.
Note: Some browsers may have trouble with the player above.
You can see the video directly at FSD Pharma’s Yuotube channel: https://www.youtube.com/watch?v=arjbsKtNioA
And there is a rumour floating on the Boards that Canada’s very own Prime Minister Justin Trudeau will be visiting Cobourg Ontario Friday, October 19th. Realistically, what else is there to see in Cobourg other than the FSD Pharma facility. Trudeau + Pot = HUGE.
Bruce Linton, CEO of Canopy Growth (aka Tweed) sells the first legal gram in St. John’s Newfoundland at 12:00 October 17, 2018.
Jeff Renwick and Richard Goldstein (l&r above) have been working together on the generic side of the pharmaceutical business for a decade. Developing drugs and drug delivery systems. Renwick has a total of 25 years in pharma and Goldstein was an investment banker. Their private company had two generic drugs in the pipeline and a good deal of work on extended release formulations.
“We’d spent our money,” said Goldstein. “We’d build a generic pharma operation in Markham Ontario. We had all the staff and the equipment and had two drugs licenced. Jeff and his team did the work on the extended release. The problem was we had no money. We went to the market to raise some but we got no traction on our first drug.”
“So we decided to start a newco three years ago,” said Goldstein. “Canntab (C.PILL) was incorporated on 4/20/2016. We did a raise in the fall of 2016 which closed January 1, 2017, at $.25. Then we did a deal with Emblem for a suite of products which used our extended release. In December 2017 we did another raise using subscription receipts: 5 million at $1.00. And on 4/20/2018 we were publicly traded”
“There was a bit of a sell-off in the summer. We were doing some deals and we brought on Hybrid Financial who reached out to brokers,” said Goldstein. “We’ve become better known in the marketplace. And our shares trended up. Right now, we’re trading around $1.85 but we’ve been as high as $2.14. We have a deal for Canada and a deal for Australia.”
Canntab is doing well because it has a solution for a set of problems which have been dogging the medical/pharmaceutical side of legal cannabis. The essential problem is dose over time. The least attractive way to deliver cannabis’s medicinal benefits is to smoke dried flower. It’s smelly, it involves all the associated health hazards and the dose varies wildly over time. When smoking, you are initially flooded with the drug, sometimes to the point of experiencing negative side effects. Oils and edibles may take hours to begin having an impact but it’s very easy to eat too much and going beyond the “Therapeutic Window.” That’s where Canntab comes in with a series of hard oral dose delivery systems that can provide stable relief over an entire day.
The solution to the problems of dose, smell and mess is a hard pill. Jeff Renwick says that Canntab Therapeutics addresses these problems by providing a better delivery system, a hard pill of natural product through a unique, proprietary technology. To bolster this Lorne Gertner, the godfather of the Canadian cannabis industry, says, “I believe the ultimate solution to the delivery of Cannabis will be through a hard pill.”
“Oils are metabolized in the liver,” said Renwick. He went on to point out that liver function varied from patient to patient depending on how well their livers were functioning, if they were drinking, how long it had been since their last meal and how efficiently a particular patient’s liver metabolized a particular oil. Even at a research level, liver metabolization makes accurate testing of medicinal cannabis products very difficult.
“We are trying to provide cannabis in a better system.” said Renwick. “Our extended release pills bypassed the liver and delivers the cannabinoids directly to the colon. The colon is a better place for extended release. We encapsulate the cannabinoids so they pass through to the colon. It is the easy way for the body to uptake cannabinoids.”
Cannatab’s current range of extended release pills with varying amounts and combinations of THC and CBD in 2.5, 5 and 10 mg pills.
“You are getting a certain dosage over a certain time period,” said Renwick. “We’re not really talking about what the drug is used for.”
Which is important and scientifically critical because it allows pharmaceutical companies to prepare baseline studies. For example, Canntab is working with a company on a clinical study which measures how much CBD is in a subject’s blood stream. Having extended release, dose-controlled, pills makes this sort of study useful and repeatable.
“We can’t say cannabis cures disease ‘x” or ‘y’,” said Renwick. “First we have to know how much of the cannabinoid is actually being taken up.”
Out of the gate, Canntab has products which will have a worldwide market. Clinical studies need pharmaceutical grade, tested, reference doses and Canntab can deliver them.
Cannabis legalization in Canada involves far more than simply the pot shop down the street. While recreational marijuana will occupy a lot of media time in the next few weeks, the fact is legalization opens up the ability of pharmaceutical companies to develop and test real medicines to treat or alleviate a multiplicity of diseases and conditions.
Canntab is working towards its own medicines and continuing to develop its line of products. It is also negotiating deals, such as the October 1 agreement with Colombia’s NewCanna, for the sale & distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain.
Legal cannabis is fast becoming a worldwide market opportunity and Canntab has the products and processes to meet that market.
Just before FSD Pharma (C.HUGE) took off we interviewed Anthony Durkacz. Very smart guy with a clear sense of where the money in cannabis is going to be made.
CNBC is covering the Canadian marijuana business and they interviewed Durkacz as well. Here is the highlight reel for Durkacz. He is especially good on the marijuana “bubble” comparing it to the internet bubble and pointing out that a lot of money was made with internet stocks even after everyone knew there was a bubble.
It is always nice to see a client do well. FSD Pharma (C.HUGE) is blazing a trail in the already hot marijuana space.
In August it traded as low as .12 but, as its story began to gain traction, it edged up to .20. However, on Friday it went up a nickel and closed at .25.
Today, on a volume which may top 100 million shares, it has touched .34.